European Medicines Agency Approves Leqembi for Early Alzheimer’s Treatment
The European Medicines Agency (EMA) has approved Leqembi, a groundbreaking treatment for Alzheimer’s disease, for patients not yet in advanced stages. Initially blocked in July due to concerns over severe side effects, the drug is now recommended for those at lower risk of brain hemorrhage. It targets patients with mild cognitive impairment or mild dementia associated with Alzheimer’s. Developed by Eisai and Biogen, Leqembi is already authorized in the U.S., Japan, and China. Experts highlight the ongoing challenges in combating Alzheimer’s, which affects millions worldwide.